Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(20%)
Results Posted
67%(4 trials)

Phase Distribution

Ph phase_4
2
20%
Ph not_applicable
1
10%
Ph phase_1
2
20%
Ph phase_2
4
40%
Ph phase_3
1
10%

Phase Distribution

2

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1
Active, not recruiting1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
Phase 42 (20.0%)
N/A1 (10.0%)

Trials by Status

withdrawn110%
completed660%
active_not_recruiting110%
not_yet_recruiting110%
recruiting110%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10